



## Regulated information

### The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available

**Gosselies, Belgium, 13 October 2017, 7am CEST - BONE THERAPEUTICS** (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, informs its shareholders that an extraordinary general shareholder meeting will be held on Monday 30 October 2017 at 11:45 am at Jean-Philippe Matagne Notary office, rue du Fort 24, 6000 Charleroi, Belgium.

The notice for the meeting, including the agenda of the day as well as the motions to vote, have been published in the Belgian Official Gazette and L'Echo on 13 October 2017.

The documents and preliminary information concerning this meeting are being made available to the shareholders and can be consulted on the website of the Company: [www.bonetherapeutics.com](http://www.bonetherapeutics.com), under the section Investors / Shareholders meeting, in compliance with the applicable law and regulations.

It is also possible to receive the documents without charge upon simple request by email to [valerie.roels@bonetherapeutics.com](mailto:valerie.roels@bonetherapeutics.com) or by telephone on +32 (0)2 529 59 90. Finally, the documents are available at the Company's headquarters: 37 Rue Auguste Piccard, 6041 Gosselies, Belgium.

#### About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

Our primary clinical focus is ALLOB<sup>®</sup>, an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB<sup>®</sup>, obtained from patient's own bone marrow and currently in Phase III development for osteonecrosis.

Bone Therapeutics' cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: [www.bonetherapeutics.com](http://www.bonetherapeutics.com).

#### Contacts

##### **Bone Therapeutics SA**

Thomas Lienard, Chief Executive Officer  
Jean-Luc Vandebroek, Chief Financial Officer  
Tel: +32 (0)2 529 59 90  
[investorrelations@bonetherapeutics.com](mailto:investorrelations@bonetherapeutics.com)

For Belgium and International Media Enquiries:

**Consilium Strategic Communications**

Amber Fennell, Jessica Hodgson and Hendrik Thys

Tel: +44 (0) 20 3709 5701

[bonetherapeutics@consilium-comms.com](mailto:bonetherapeutics@consilium-comms.com)

For French Media and Investor Enquiries:

**NewCap Investor Relations & Financial Communications**

Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau

Tel: + 33 (0)1 44 71 94 94

[bone@newcap.eu](mailto:bone@newcap.eu)

For US Media and Investor Enquiries

**Westwicke Partners**

John Woolford

Tel: + 1 443 213 0506

[john.woolford@westwicke.com](mailto:john.woolford@westwicke.com)

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

---